Enliven Therapeutics (ELVN) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
0
Operating Income
-104.6M
Net Income
-89.0M
Balance Sheet Metrics
Total Assets
325.8M
Total Liabilities
15.9M
Shareholders Equity
309.8M
Debt to Equity
0.05
Cash Flow Metrics
Operating Cash Flow
-68.6M
Free Cash Flow
-73.2M
Revenue & Profitability Trend
Enliven Therapeutics Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 104.6M | 83.5M | 38.8M | 24.8M | 9.3M |
| Operating Income | -104.6M | -83.5M | -38.8M | -24.8M | -9.3M |
| Pre-tax Income | -88.8M | -71.6M | -37.7M | -24.7M | -19.0M |
| Income Tax | 232.0K | - | - | - | - |
| Net Income | -89.0M | -71.6M | -37.7M | -24.7M | -19.0M |
| EPS (Diluted) | - | -$2.01 | -$0.92 | -$0.60 | -$0.46 |
Income Statement Trend
Enliven Therapeutics Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 318.1M | 266.2M | 77.8M | 110.7M | 130.6M |
| Non-Current Assets | 7.6M | 5.7M | 5.5M | 2.7M | 416.0K |
| Total Assets | 325.8M | 271.9M | 83.3M | 113.3M | 131.0M |
| Liabilities | |||||
| Current Liabilities | 15.9M | 25.9M | 9.7M | 5.8M | 1.5M |
| Non-Current Liabilities | 0 | 67.0K | 150.4M | 150.5M | 149.8M |
| Total Liabilities | 15.9M | 26.0M | 160.1M | 156.2M | 151.3M |
| Equity | |||||
| Total Shareholders Equity | 309.8M | 245.9M | -76.8M | -42.9M | -20.3M |
Balance Sheet Composition
Enliven Therapeutics Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -89.0M | -71.6M | -37.7M | -24.7M | -19.0M |
| Operating Cash Flow | -68.6M | -60.6M | -33.8M | -20.8M | -8.8M |
| Investing Activities | |||||
| Capital Expenditures | -44.0K | -149.0K | -612.0K | -191.0K | -461.0K |
| Investing Cash Flow | -36.0M | -148.4M | -612.0K | -191.0K | -461.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 39.2M | 233.9M | -2.4M | -1.0M | 130.5M |
| Free Cash Flow | -73.2M | -61.4M | -32.7M | -19.3M | -9.0M |
Cash Flow Trend
Enliven Therapeutics Key Financial Ratios
Valuation Ratios
Forward P/E
-8.56
Price to Book
3.45
PEG Ratio
-8.56
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-31.30%
Return on Assets
-21.36%
Financial Health
Current Ratio
21.06
Debt to Equity
0.23
Beta
0.95
Per Share Data
EPS (TTM)
-$1.92
Book Value per Share
$5.88
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| elvn | 1.2B | - | 3.45 | -31.30% | 0.00% | 0.23 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 2.1B | 3.17 | 1.44 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.